1. Home
  2. SJT vs BMEA Comparison

SJT vs BMEA Comparison

Compare SJT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SJT

San Juan Basin Royalty Trust

N/A

Current Price

$3.55

Market Cap

172.0M

Sector

Energy

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.20

Market Cap

138.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SJT
BMEA
Founded
1980
2017
Country
United States
United States
Employees
495
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.0M
138.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SJT
BMEA
Price
$3.55
$1.20
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$9.83
AVG Volume (30 Days)
191.3K
1.1M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.41
$0.87
52 Week High
$7.00
$3.07

Technical Indicators

Market Signals
Indicator
SJT
BMEA
Relative Strength Index (RSI) 32.06 38.35
Support Level N/A $1.05
Resistance Level $5.87 $1.46
Average True Range (ATR) 0.17 0.10
MACD -0.03 -0.01
Stochastic Oscillator 16.88 23.68

Price Performance

Historical Comparison
SJT
BMEA

About SJT San Juan Basin Royalty Trust

San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: